Next Article in Journal
The Application of Fe-EDTA and Sodium Silicate Affects the Polyphenols Content in Broccoli and Radish Sprouts
Next Article in Special Issue
Evaluation of Immune Dysregulation in an Austrian Patient Cohort Suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Previous Article in Journal
BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme
Previous Article in Special Issue
Bioenergetic and Proteomic Profiling of Immune Cells in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients: An Exploratory Study
Article

Potential of Activin B as a Clinical Biomarker in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

1
Institute of Microbiology and Virology, Rīga Stradiņš University, 5 Ratsupites Str., LV-1067 Riga, Latvia
2
Department of Infectology, Riga Stradins University, LV-1007 Riga, Latvia
*
Author to whom correspondence should be addressed.
Academic Editors: Michael Grusch, Jose M. Valdivielso and Vladimir N. Uversky
Biomolecules 2021, 11(8), 1189; https://doi.org/10.3390/biom11081189
Received: 16 June 2021 / Revised: 9 August 2021 / Accepted: 10 August 2021 / Published: 11 August 2021
(This article belongs to the Special Issue Biomarkers in Chronic Fatigue Syndrome (ME/CFS))
Reliable serum biomarkers are of immense need for diagnostic purposes of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)—a disabling and complex disease for which diagnosis is mainly based on clinical symptoms. The aim of this study was to evaluate a possible diagnostic potential of activin B by directly comparing 134 cases of ME/CFS with 54 healthy controls. Analyses of human activin B level in plasma samples were performed using a validated human activin B ELISA assay. The results of the study show that activin B levels did not differ statistically significantly between ME/CFS patients and healthy controls (p = 0.6511). No gender or age-related differences in activin B levels were observed in the ME/CFS group and healthy controls. The level of activin B tended to decrease with increasing visual analogue scale score (r = −0.2004; p = 0.5085) nevertheless the results obtained so far does not support the clinical utility of activin B as a biomarker for ME/CFS. View Full-Text
Keywords: ME/CFS; human activin B; visual analogue scale ME/CFS; human activin B; visual analogue scale
Show Figures

Figure 1

MDPI and ACS Style

Gravelsina, S.; Nora-Krukle, Z.; Vilmane, A.; Svirskis, S.; Vecvagare, K.; Krumina, A.; Murovska, M. Potential of Activin B as a Clinical Biomarker in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Biomolecules 2021, 11, 1189. https://doi.org/10.3390/biom11081189

AMA Style

Gravelsina S, Nora-Krukle Z, Vilmane A, Svirskis S, Vecvagare K, Krumina A, Murovska M. Potential of Activin B as a Clinical Biomarker in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Biomolecules. 2021; 11(8):1189. https://doi.org/10.3390/biom11081189

Chicago/Turabian Style

Gravelsina, Sabine, Zaiga Nora-Krukle, Anda Vilmane, Simons Svirskis, Katrine Vecvagare, Angelika Krumina, and Modra Murovska. 2021. "Potential of Activin B as a Clinical Biomarker in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)" Biomolecules 11, no. 8: 1189. https://doi.org/10.3390/biom11081189

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop